Abstract
Abstract Breast cancer represents the most commonly diagnosed cancer worldwide, accounting for approximately one in eight cancers diagnosed. Despite significant advances in the diagnosis and detection of this disease, there is still a great need for more effective therapies to combat the invasive forms, especially those with a high incidence of metastasis. For that reason, bioactive molecules as peptides, including bovine lactoferricin (LfcinB), have been investigated. In this sense, there are reports that 20RRWQWR25 motif derivate from the LfcinB has shown activity against different cancer cell lines. Thus, current studies are being carried out with synthetic derivatives (linear, palindromic, dimer and tetrameric structures) that contain the 20RRWQWR25 motif in order to increase its activity against cancer cell lines by altering its hydrophobicity and net positive charge. In this regard, studies have focused on the use of LfcinB derivatives to combat breast cancer cell lines, with encouraging results. Therefore, in this mini-review, we present the state of the art regarding the activity of LfcinB and its analogs against breast cancer cell lines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.